DELPHI GENETICS - DELPHI GENETICS YOUR CERTIFIED CDMO PARTNER FOR GMP PLASMID DNA BIOPRODUCTION

SOMERSET, N.J. and GOSSELIES, BELGIUM – February 23, 2021 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and Delphi Genetics, a plasmid DNA (pDNA) cell and gene therapy contract development and manufacturing organization (CDMO) based in Gosselies, Belgium, today announced that they have entered into a final and definitive agreement whereby Catalent will acquire 100% of the shares of Delphi Genetics. Catalent is also announcing the launch of pDNA development and manufacturing services at its Rockville, Maryland facility. Together, the addition of pDNA technology and production capabilities marks a significant milestone for Catalent Cell & Gene Therapy. https://www.catalent.com/catalent-news/catalent-to-acquire-delphi-genetics-and-launch-us-plasmid-manufacturing-site-to-establish-global-pdna-development-and-manufacturing-capabilities/

Delphi Genetics announces today that it has received the coveted GMP certificate, issued by the AFMPS, covering its brand new state-of-the-art GMP manufacturing suites. « The approval of these additional three suites allows Delphi Genetics to very significantly enhance its production capacities for plasmid DNA manufacturing and further assist the development of gene therapy candidates and DNA-based therapies », commented François Blondel, Chairman of the board of Directors and CEO. « This approval, and the capacity expansion, are a very significant step forward in the growth of Delphi Genetics. They will allow us to significantly reduce lead time and efficiently support both our existing customer base as well as future customers, mostly active in Gene Therapy using viral vectors », he added.

Delphi Genetics announces today that it has obtained highly promising results with its Gene Therapy-based Covid-19 therapeutic candidate in in-vitro experiments. With solid expertise in DNA development and production, Delphi Genetics has developed an innovative approach to treat patients infected by Covid-19. The principle consists in inactivating and destroying the virus in cells where the virus is present. The main objective of this therapy is to cure the disease once patients get infected. The company has three potential candidates, all three being tested with the collaboration of ULiège laboratories and showing promising results on human cells, with the lead candidate being able to 100% inhibit the virus, “far beyond expectations” says Cédric Szpirer, Founder and Executive Director, who leads the project.